The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. hold a median 12-month price target of $18 — +59.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Lumexa Imaging Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (57): Analysts have, on balance, been raising their forecasts.
Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Lumexa Imaging Holdings, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on LMRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +59.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 May 2026 | Barclays | Maintains | Overweight | $15 → $9.00 |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 9 Feb 2026 | Raymond James | Upgrade | Strong Buy | — |
| 5 Jan 2026 | Barclays | Initiates | Overweight | — |
| 5 Jan 2026 | Deutsche Bank | Initiates | Buy | — |
| 5 Jan 2026 | Jefferies | Initiates | Buy | — |
| 5 Jan 2026 | Leerink Partners | Initiates | Outperform | — |
| 5 Jan 2026 | Raymond James | Initiates | Outperform | — |
| 5 Jan 2026 | Wells Fargo | Initiates | Overweight | — |
| 5 Jan 2026 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 69% of US stocks
Cheaper than 50% of US stocks
Cheaper than 14% of US stocks
Higher than 37% of US stocks
Higher than 14% of US stocks
Higher than 54% of US stocks
Higher than 25% of US stocks
Higher than 37% of US stocks
Higher than 36% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LMRI appears on the weeks it earns a place.
Lumexa Imaging announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.
Why it matters — The announcement signals the upcoming release of key financial and operational data that will provide insight into the company's recent performance.
The 8 Wall Street analysts covering Lumexa Imaging Holdings, Inc. have a median 12-month price target of $18, with estimates ranging from $9 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Lumexa Imaging Holdings, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lumexa Imaging Holdings, Inc. 2 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Lumexa Imaging Holdings, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (57 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +59.9% from the last close, and Ticker Nerd's factor model ranks Lumexa Imaging Holdings, Inc. 2 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Lumexa Imaging Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $23 over the next 12 months.
Lumexa Imaging Holdings, Inc. is a healthcare services company that owns and operates outpatient diagnostic imaging centers across the United States.
The most recent item we track (GlobeNewsWire, 29 July 2026): "Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date". Lumexa Imaging announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.
Lumexa Imaging Holdings, Inc. is a healthcare services company that owns and operates outpatient diagnostic imaging centers across the United States. The company focuses on providing a broad range of medical imaging procedures, including magnetic resonance imaging, computed tomography, positron emission tomography, X-ray, ultrasound, and mammography for both diagnostic and screening purposes. Lumexa Imaging Holdings, Inc. plays a key role in the outpatient care ecosystem by offering advanced imaging capabilities in lower-cost, non-hospital settings, supporting physicians, health systems, and patients with accessible imaging options. Formed in 2018 in partnership with Charlotte Radiology and private equity firm Welsh, Carson, Anderson & Stowe, it has grown into one of the largest national providers of diagnostic imaging services, operating over a hundred centers in multiple states. Headquartered in Raleigh, North Carolina, the company emphasizes clinical quality, state-of-the-art technology, and an integrated platform designed to scale across diverse regional markets.
CEO Ms. Caitlin Zulla · 4,064 employees · United States · https://www.lumexaimaging.com